A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants
Research type
Research Study
Full title
A Phase 1/2a Study of REGN7041 (anti-CD3 monoclonal antibody) in Participants with Active Noninfectious Uveitis Affecting the Posterior Segment
IRAS ID
1013079
Contact name
Angelica Canedo
Contact email
Sponsor organisation
Regeneron Pharmaceuticals Inc.
Clinicaltrials.gov Identifier
Research summary
This study is researching an experimental drug called REGN7041 (also referred to as “study drug”). The study is focused on patients who have active inflammation inside of the eye without any signs of infection.
The aim of the study is to see how safe and tolerable the study drug is. This is the first time the study drug is being tested in humans.
The study is looking at several other research questions, including:
• What side effects may happen from taking the study drug
• How much study drug is in the blood and the fluid in the eye at different times
• Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
The main questions this study will answer are:
- What side effects may participants experience after receiving treatment with REGN7041?
- How does REGN7041 move through the body over time (pharmacokinetics)?
- How does the immune system respond to REGN7041 (immunogenicity)?
This study will include about 72 participants from around the world.
The sponsor of the study is Regeneron Pharmaceuticals, Inc.REC name
Wales REC 1
REC reference
25/WA/0359
Date of REC Opinion
9 Feb 2026
REC opinion
Further Information Favourable Opinion